Cirrose biliar primária e miopatia: uma rara associação by Migueletto, Bruno Cupertino et al.
165
REV. HOSP. CLÍN. FAC. MED. S.PAULO 54(5):165-168, 1999SEPTEMBER-OCTOBER
From the Department of Clinical Medicine,
University of São Paulo School of Medicine,
São Paulo - Brazil.
PRIMARY BILIARY CIRRHOSIS AND MYOPATHY: AN
UNCOMMON ASSOCIATION
Bruno Cupertino Migueletto, Abrahão Elias Hallack Neto, Elaine Zamora
Domingues, Pedro Paulo Neves de Castro, Hartmut Stocker, Sueli K. Nagahashi
Marie, Luiz Pedro Meireles and Milton Hideaki Arai
RHCFAP/ 2985
MIGUELETTO, B. C. et al. - Primary biliary cirrhosis and myopathy: an uncommum association. Rev. Hosp. Clín. Fac. Med. S. Paulo 54 (5):165-168,
1999.
SUMMARY: Primary biliary cirrhosis (PBC) is a cholestatic liver disease, which is characterized by a chronic inflammatory destruction of intrahepatic
bile ducts. It is a rare disorder whose precise etiology is still to be elucidated. Even though the liver is the principal target of PBC, other organ systems
also might be affected. Muscular involvement has rarely been described in this disease, and in the majority of cases, muscular weakness has been
interpreted as polymyositis. We report the case of a 48-year-old woman suffering from classic PBC, in association with a myopathy whose histological
features are distinct from the cases reported before. We also performed a MEDLINE research for PBC and concomitant muscular diseases.
DESCRIPTORS: Primary biliary cirrhosis. Myopathy.
Primary biliary cirrhosis (PBC) is a
rare disease, characterized by chronic
cholestasis. Its etiology is still not
entirely understood, but clinical,
laboratory and histopathologic findings
strongly suggest an autoimmune pro-
cess. Histologically the disorder is
characterized by an inflammatory
process that leads to the destruction of
intrahepatic bile ducts and results in
fibrosis of the portal tracts and finally
in hepatic failure. Up to 84% of
patients with PBC also suffer from at
least one more disorder classified as
auto immune, with Sjogren Syndrome,
auto immune thyroiditis, and systemic
sclerosis being the most frequent ones.
Besides the liver, which is the
principal target of PBC, other organs
might also be affected. However,
muscular damage has rarely been
reported in patients with PBC, and in
these cases the nature of the myopathy
has been poorly characterized.
We report the case of a patient with
histologically proven PBC with
associated muscular disease. We de-
scribe the histologic features of this
myopathy.
A MEDLINE research yielded
twenty case reports on PBC in asso-
ciation with muscular involvement,
which was generally found to be
polymyositis.
CASE  REPORT
Our patient, a 48-year-old white
woman, sought medical assistance be-
cause of proximal muscular weakness
of upper and lower extremities that had
started four years earlier. She also com-
plained of generalized prurigo as well
as darkening of her skin, principally of
her trunk and forearms, and hypertri-
chosis of her arms, which had been
troubling her for two years. Eight years
earlier, she had undergone total hyster-
ectomy and bilateral oophorectomy
because of ovarian cysts. Estrogen re-
placement was initiated and maintained
ever since. In 1995 osteoporosis was
diagnosed.
The patient reported that she did
not drink alcohol on a regular basis and
that she had not received any trans-
fusions.
On physical examination she did
not show any stigmas of chronic liver
disease. She had no fever, she did not
have jaundice, and her liver was
normal in size. Muscular strength was
grade 4 in proximal muscles of upper
and lower extremities. There were no
further alterations on physical exam.
Laboratory data acquired during
investigation include the following:
AST 123U/L (10-30U/L), ALT 84 U/
L (10-36 U/L), gGT 543 U/L (7-32 U/
L), Alkaline Phosphatase 941 U/L (32-
104 U/L), Creatine Kinase 380U/L
(24-173U/L), LDH 465 U/L, Choles-
terol 247 mg/dl. Serum immunoglo-
bulins were increased: IgG 1767 mg/
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dl, (952-1538); IgA 703 mg/dl (153-
359) IgM 617 mg/dl (73-171).
Erythrocyte sedimentation rate was
78 mm.
Immunofluorescence was positive
showing a granular cytoplasmic pattern
(1:160).
Anti-DNA, SSA, SSB, SM, and
RNP autoantibodies were absent. Anti-
smooth muscle and anti-liver-kidney
antibodies could not be detected.
Serum complement was normal.
Serologic testing for viral hepatitis was
negative.
Total serum bilirubin and fractions
were within normal range. There were
no alterations in coagulation tests.
Serum albumine was 4.4 mg/dl
TSH was 0.9 um/L (0.25-4.0).
Antimitochondrial antibodies
(AMA) were present (titre>1:320).
ECG showed sinus rhythm with
frequent atrial and ventricular pre-
mature complexes.
Chest X-ray was normal.
Bone densitometry of the lumbar
spine and of the neck of femur confir-
med the diagnosis of osteoporosis. (T
index lumbar spine:-3.83 DP/ T index
neck of femur -4.06 DP)
On abdominal ultrasonography, the
patient’s liver was found to be homo-
geneously enlarged without evidence
of congestion of the bile tree.
Liver biopsy (Microphotograph 1)
showed moderate fibrous expansion of
the portal tracts with preservation of
liver architecture. Portal tracts were
densely infiltrated with lymphocytes a
few plasmocytes, and a significant
number of neutrophils, with focal
invasion of the portal tracts. Prolife-
ration of bile ductules was evident in
the periphery of portal tracts, and there
was discreet lobular inflammatory
activity.
The histopathologic findings were
compatible with chronic hepatobiliary
disease in moderate activity, suggesting
primary biliary cirrhosis.
Focussing on the patient’s muscu-
Fig. 1 - Liver biopsy: proliferation of bile ductules infiltrated with lymphocytes.
Fig. 2 - Muscle biopsy. We found accentuated variation of muscle fiber size with the presence of
ragged, rounded degenerating fibers.
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lar weakness, we had an electromyo-
graphy performed, which revealed
chronic myopathy affecting all extre-
mities with a clear proximal distri-
bution pattern. The findings were com-
patible with polymyositis. A biopsy
specimen (microphotograph 2) was ob-
tained from the left brachial biceps. On
examination we found accentuated
variation of muscle fiber size with the
presence of ragged, rounded, degener-
ating fibers, as well basophilic necrotic
fibers with subsarcolemmal vacuoles.
Angular fibers were present with nuclei
condensed into aggregates, a phenom-
enon known as nuclear clumps. We
also noted fibers with centrally located
nuclei. There was proliferation of con-
nective tissue both in endomysium and
perimysium.
When stained for oxidative reac-
tions, some fibers showed disarrange-
ment. Occasional fibers showed in-
creased granulation in the SDH stain
that indicated mitochondrial prolifera-
tion. Numerous fibers were identified
by the acid phosphatase reaction, indi-
cating lysosomal activity. A few regen-
erating fibers reacted positively when
stained with the alkaline phophatase
reaction. We noted a slight predomi-
nance of type one fibers.
The final diagnosis was PBC with
muscular involvement.
We initiated treatment with cho-
lestyramine 4.0 g, p.o. three times a
day, and ursodeoxycholic acid 300 mg,
p.o. b.i.d., as well as calcium car-
bonate, vitamin D, and alendronate for
osteoporosis. The patient was dis-
charged from hospital and is conti-
nuing treatment on an outpatient basis.
DISCUSSION
PBC is a rare, progressive, cho-
lestatic liver disease of unknown
etiology. Morphologically it is charac-
terized by the destruction of intra-
hepatic bile ductules. PBC is frequently
associated with other autoimmune
disorders. The most frequent ones are
Sjogren syndrome, rheumatoid ar-
thritis, and systemic sclerosis (CREST
syndrome).
In this article we present the case
of a 48-year-old patient with PBC and
a coexisting myopathy. The diagnosis
of PBC was based on clinical data, on
elevated levels of serum alkaline
phosphatase, gGT, and IgM, as well as
the presence of circulating antimi-
tochondrial antibodies (AMA). The
diagnosis was histologically confirmed
by liver biopsy.
Concerning the patient’s muscular
weakness, we found elevated creatine
kinase, alterations in EMG, and finally
a highly pathologic muscular histology.
Muscular disease in patients with
PBC has been poorly defined. There
are few articles in medical literature
that deal with this subject. In 1993
Varga and co-workers described two
cases of asymptomatic PBC with a
syndrome of severe progressive myo-
pathy, cardiomyopathy, and gastro-
intestinal dysmotility. They also re-
viewed literature focussing on this rare
association. They found most of the
previous reports describing focal
mononuclear inflammatory infiltrates
generally localized in the perivascular
spaces, in addition to other alterations
compatible with inflammatory myopa-
thy.
In our case, there was little perivas-
cular and endomysial inflammation
except for rare fibers with mito-
chondrial proliferation. These findings
are symptomatic of a mixture of
neurogenic and primary myogenic
muscular disorder.
In spite of the patient’s proximal
muscular weakness, elevated levels of
creatine kinase, and the results of EMG
that all suggested polymyositis, mus-
cular biopsy did not reveal any charac-
teristics of active inflammatory muscu-
lar disease.
The findings reveal a chronic
process that is compatible with the long
duration of the muscular disease. Since
our patient underwent biopsy four
years after the onset of her muscular
disease, we must consider the possibi-
lity of a different histologic pattern at
the beginning of the disease. On
possibility includes a more distinct
inflammatory pattern.
The coexistence of PBC and mus-
cular disease raises the possibility of a
common pathogenic mechanism for
both processes. PBC is associated with
various immunologic abnormalities.
Patients typically have elevated levels
of IgM, circulating immune com-
plexes, and 90% of patients are positive
for antimitochondrial antibodies.
Antimitochondrial antibodies may
also be detected in patients with diffuse
muscle weakness and mitochondrial
abnormalities. In these cases, though,
the specificity of these antibodies has
not been defined yet, and the signifi-
cance of this finding in diffuse muscle
weakness and mitochondrial abnor-
malities is still to be elucidated.
According to Varga2 and co-
workers, antimitochondrial antibodies
directed against specific proteins
present in the skeletal muscle and other
organs could be responsible for the
development of muscular disease in
patients with PBC.
In this case, other primary and
secondary myopathies have to be
excluded. Autoimmune thyroiditis is
very frequent in patients with PBC;
therefore, hyperthyroidism and hypo-
thyroidism have to be ruled out as
causes of muscular weakness. Other
causes such as drug-induced myo-
pathies, hyperparathyroidism, hyper-
adrenalism, and other inflammatory
myopathies should be considered too.
An interesting aspect of this case is
the patient’s osteoporosis confirmed by
densitometry. Osteoporosis is a fre-
quent extra hepatic manifestation of
PBC. Even though it shares the histo-
logic features of osteoporosis in post-
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menopausal women, its pathogenic
mechanism is unclear, and there is no
consensus on how to treat this con-
dition. Besides her liver disease bilat-
eral oophorectomy represents a further
predisposing factor for osteoporosis in
our patient. Treatment with estrogens
is usually avoided because of its well-
known cholestatic effect.
However, in a non-controlled,
retrospective trial performed in 1994,
Crippin and colleagues found that
oestrogen replacement in patients with
PBC and osteoporosis did not worsen
cholestasis either clinically or bio-
chemically.
Another observation from this
study was that calcium and vitamin D
were not sufficient for reverting bone
loss in patients with PBC.
In 1999 Olsson et al.5, who
analyzed the effect of estrogens on
osseous density in nine women with
osteoporosis and PBC, found treatment
with calcium and vitamin D to be
effective and safe. The small number
of patients in these trials, however,
makes it difficult to recommend
oestrogen treatment for all women with
osteoporosis and PBC. In our case, we
opted for treating osteoporosis with
calcium, vitamin D, and alendronate
Treatment of myopathy generally
requires the use of corticoids. In this
case, however, benefits of an increased
muscular strength have to be consi-
dered against the risks of aggravating
the patient’s osteoporosis in addition to
the other complications this treatment
may cause.
This article describes the case of a
patient with PBC and myopathy, an
infrequent association, complicated by
osteoporosis. The physiopathology of
this association is still not understood
but may be related to the presence of
antimitochondrial antibodies.
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A cirrose biliar primária (CBP) é
uma doença hepática colestática crô-
nica de etiologia desconhecida e rara.
Apesar do principal órgão acometido
na CBP ser o fígado, outros órgãos
podem também ser afetados. O acome-
timento muscular raramente tem sido
relatado em pacientes com CBP e na
maioria destes casos, a fraqueza mus-
cular tem sido interpretada como
Polimiosite. Nós relatamos o caso de
uma mulher de 48 anos com CBP e
miopatia com achados histopatológicos
distintos dos casos anteriormente
descritos e fizemos uma revisão da
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